Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

(2010) Siqing Fu et al.   CANCER

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

(2010) Fang Fang et al.   CANCER

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

(2009) N Steele et al.   BRITISH JOURNAL OF CANCER

Targeting DNA Methylation

(2009) J.-P. J. Issa et al.   CLINICAL CANCER RESEARCH

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

(2008) T. Qin et al.   BLOOD

Valproic acid resensitizes cisplatin-resistant ovarian cancer cells

(2008) Ching-Tai Lin et al.   CANCER SCIENCE

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

(2008) F. Braiteh et al.   CLINICAL CANCER RESEARCH

Pharmaceutical Management of Ovarian Cancer

(2008) Maurie Markman   DRUGS

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

(2008) Gautam Borthakur et al.   LEUKEMIA & LYMPHOMA

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

(2008) Elizabeth A. Griffiths et al.   SEMINARS IN HEMATOLOGY